크로모블라스토미코시스 치료 시장 : 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the chromoblastomycosis treatment market size is projected to expand from USD 1.12 billion in 2025 and USD 1.18 billion in 2026 to USD 1.54 billion by 2031, registering a CAGR of 5.45% between 2026 to 2031.

This report is Segmented by Treatment Type (Antifungal Therapy, Surgical Excision, Cryotherapy, Thermotherapy, Combination), Drug Class (Azoles, Allylamines, Polyenes, Adjunctive), Route of Administration (Oral, Topical, Parenteral), End User (Hospitals, Dermatology Clinics, Specialty Care, Homecare), and Geography (North America, Europe, Asia-Pacific, and More). Forecasts are in Value (USD).

Global Chromoblastomycosis Treatment Market Trends and Insights

Rising Need for Long-Duration Systemic Antifungal Therapy

The chromoblastomycosis treatment market benefits from the extended therapy durations required by most patients. Standard treatments last 8 to 36 months, with itraconazole typically administered at daily doses of 200 to 400 mg. This prolonged regimen results in significant cumulative drug demand for each patient episode. Itraconazole remains the primary agent for mild to severe cases, while terbinafine is frequently used in combination therapies. Cure rates for itraconazole monotherapy range from 15% to 80%, often necessitating extended treatments, second-line therapies, or combined regimens, further driving market demand. This trend ensures a consistent demand profile compared to acute infections, as consumption builds over extended periods.

Growing Use of Combination Therapy for Refractory Lesions

The market is witnessing a shift toward combination therapies for moderate to severe cases. Evidence shows improved outcomes when itraconazole is paired with terbinafine for Fonsecaea pedrosoi infections. DAT therapy, combining debulking, intralesional amphotericin B, and oral terbinafine, has emerged as a curative option for patients unresponsive to standard treatments. Adjunctive photodynamic therapy has demonstrated an 80% to 90% reduction in lesion size after six applications, highlighting the growing role of device-based modalities. Multi-modal approaches, such as combining cryotherapy, itraconazole, and topical 5-fluorouracil, are gaining clinical acceptance, achieving significant lesion clearance within months.

Long Treatment Duration and Poor Adherence

Poor adherence remains a significant challenge in the chromoblastomycosis treatment market. Daily or pulse itraconazole regimens, lasting 8 to 36 months, often face discontinuation due to costs, side effects, and the slow initial response of lesions. Interrupted therapy creates selective pressure, with studies showing higher itraconazole MICs in isolates during treatment, indicating resistance from incomplete cycles. This reduces clinical success and undermines the reliability of first-line therapy. Standard itraconazole's food-dependent absorption adds to challenges in lower-resource settings, while super-bioavailability itraconazole, developed to address this, remains unaffordable in many endemic areas.

Other drivers and restraints analyzed in the detailed report include:

1. Persistent Diagnostic Delay in Endemic Rural Care Pathways
2. Public Procurement and Donation Models for Itraconazole
3. Limited Clinical Trial Evidence and Standardized Guidelines

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

In 2025, Antifungal Drug Therapy accounted for 58.45% of the chromoblastomycosis treatment market, highlighting the continued reliance on systemic azoles and allylamines for managing various disease severities. This includes itraconazole monotherapy for localized cases and complex oral regimens for chronic or severe lesions. Combination Therapy is projected to grow at a 5.66% CAGR from 2026 to 2031, driven by a shift toward multi-drug and multi-modal approaches when monotherapy proves insufficient.

Published evidence supports improved outcomes in moderate to severe cases when systemic drugs are combined with cryotherapy, laser treatments, or intralesional amphotericin B. Immunomodulatory agents like topical imiquimod are increasingly used alongside systemic azoles for challenging lesions, bridging infectious disease treatment and dermatology. While surgical excision and cryotherapy remain relevant for localized cases, the market is moving toward pharmaceutical-centered combinations, with physical modalities serving as complementary options. Drug-based protocols are expected to dominate the market during the forecast period.

Azoles held a 71.75% share of the chromoblastomycosis treatment market in 2025, reflecting their position as the leading drug class. Itraconazole remains the global first-line treatment, supported by established prescribing patterns in endemic regions. Posaconazole, the primary second-line azole, has regulatory approval for chromoblastomycosis and mycetoma, with case data showing successful outcomes in 9 of 11 patients.

Allylamines, led by terbinafine, are gaining traction due to their effectiveness in combination therapies and select monotherapy cases, with a 66% complete healing rate reported in F. pedrosoi infections over 12 months. Polyenes like amphotericin B are limited to severe cases due to toxicity concerns, while adjunctive agents such as flucytosine and topical imiquimod hold niche relevance. Drug repurposing efforts are identifying compounds with potential synergy with itraconazole, indicating gradual diversification within the market.

Complete Report Scope:

• By Treatment Type
  • Antifungal Drug Therapy
  • Surgical Excision
  • Cryotherapy
  • Thermotherapy
  • Combination Therapy
• By Drug Class
  • Azoles
  • Allylamines
  • Polyenes
  • Adjunctive Antifungal Agents
• By Route Of Administration
  • Oral
  • Topical
  • Parenteral
• By End User
  • Hospitals
  • Dermatology Clinics
  • Specialty Care Centers
  • Homecare And Ambulatory Settings
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

In 2025, North America held a 38.95% share of the chromoblastomycosis treatment market, maintaining its position as the largest regional contributor. The region benefits from advanced dermatology infrastructure, access to branded azoles like posaconazole and voriconazole, and higher adoption of multi-drug combination protocols compared to many endemic low-income markets. The United States drives most of this value due to its academic medical centers specializing in travel-acquired and immigrant-associated cases. Canada and Mexico contribute smaller volumes, with Mexico's northern semi-arid regions showing distinct infection patterns compared to humid-region diseases caused by Fonsecaea pedrosoi. Europe is also seeing a rise in non-endemic cases linked to migration from Africa and Latin America, highlighting challenges in timely diagnosis outside specialized tropical care.

Asia-Pacific is projected to grow at a 7.88% CAGR from 2026 to 2031, making it the fastest-growing region in the chromoblastomycosis treatment market. Improved case detection in India, China, South Korea, and Southeast Asia is addressing underreported cases. WHO data recorded 1,394 cases in Asia through 2024, including 169 in India and 71 in Japan, though the actual burden is likely higher due to incomplete surveillance. A 2026 study from Kerala identified F. nubica as the predominant species, emphasizing the need for region-specific treatment approaches. India's strong generic pharmaceutical sector provides a cost-effective supply of itraconazole and terbinafine as diagnoses increase.

Latin America remains the primary disease-burden center in the chromoblastomycosis treatment market, with Brazil accounting for one of the largest national caseloads globally. Brazil's public provision of itraconazole through a dedicated implantation mycoses program offers suppliers better volume visibility but limits premium pricing. Fonsecaea pedrosoi caused 84.1% of registered cases in Latin America and the Caribbean, enabling more standardized treatment protocols compared to Asia or Africa.

1. Astellas Pharma
2. Aurobindo Pharma
3. Bayer
4. Cipla
5. Dr. Reddys Laboratories Limited
6. Gilead Sciences
7. Glenmark Pharmaceuticals
8. GlaxoSmithKline
9. Hikma Pharmaceuticals
10. Johnson & Johnson
11. Merck
12. Mycovia Pharmaceuticals
13. Novartis
14. Pfizer
15. Sanofi
16. SCYNEXIS
17. Sun Pharmaceuticals Industries
18. Teva Pharmaceutical Industries
19. Viatris

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 Study Assumptions and Market Definition
• 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET LANDSCAPE

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Need for Long-Duration Systemic Antifungal Therapy
  • 4.2.2 Persistent Diagnostic Delay in Endemic Rural Care Pathways
  • 4.2.3 Public Procurement and Donation Models for Itraconazole Access
  • 4.2.4 Growing Use of Combination Therapy for Refractory Lesions
  • 4.2.5 Underuse of Species-Level Identification and Antifungal Susceptibility Testing
  • 4.2.6 Scarcity of Affordable Newer Triazoles in Endemic Markets
• 4.3 Market Restraints
  • 4.3.1 Long Treatment Duration and Poor Adherence
  • 4.3.2 Limited Clinical Trial Evidence and Standardized Guidance
  • 4.3.3 Low Commercial Incentive Due to Disease Neglect and Regional Concentration
  • 4.3.4 Limited Access to Diagnostics and Specialist Dermatology Care
• 4.4 Value/Supply Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Bargaining Power of Suppliers
  • 4.7.2 Bargaining Power of Buyers
  • 4.7.3 Threat of New Entrants
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 MARKET SIZE AND GROWTH FORECASTS (VALUE, USD)

• 5.1 By Treatment Type
  • 5.1.1 Antifungal Drug Therapy
  • 5.1.2 Surgical Excision
  • 5.1.3 Cryotherapy
  • 5.1.4 Thermotherapy
  • 5.1.5 Combination Therapy
• 5.2 By Drug Class
  • 5.2.1 Azoles
  • 5.2.2 Allylamines
  • 5.2.3 Polyenes
  • 5.2.4 Adjunctive Antifungal Agents
• 5.3 By Route Of Administration
  • 5.3.1 Oral
  • 5.3.2 Topical
  • 5.3.3 Parenteral
• 5.4 By End User
  • 5.4.1 Hospitals
  • 5.4.2 Dermatology Clinics
  • 5.4.3 Specialty Care Centers
  • 5.4.4 Homecare And Ambulatory Settings
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 India
    • 5.5.3.3 Japan
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products and Services, Recent Developments)
  • 6.3.1 Astellas Pharma Inc.
  • 6.3.2 Aurobindo Pharma Limited
  • 6.3.3 Bayer AG
  • 6.3.4 Cipla Limited
  • 6.3.5 Dr. Reddys Laboratories Limited
  • 6.3.6 Gilead Sciences, Inc.
  • 6.3.7 Glenmark Pharmaceuticals Limited
  • 6.3.8 GSK plc
  • 6.3.9 Hikma Pharmaceuticals PLC
  • 6.3.10 Johnson & Johnson
  • 6.3.11 Merck & Co., Inc.
  • 6.3.12 Mycovia Pharmaceuticals, Inc.
  • 6.3.13 Novartis AG
  • 6.3.14 Pfizer Inc.
  • 6.3.15 Sanofi
  • 6.3.16 SCYNEXIS, Inc.
  • 6.3.17 Sun Pharmaceutical Industries Limited
  • 6.3.18 Teva Pharmaceutical Industries Limited
  • 6.3.19 Viatris Inc.

7 MARKET OPPORTUNITIES AND FUTURE OUTLOOK

• 7.1 White-Space and Unmet-Need Assessment